Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
Nutritional intervention with a partially hydrolyzed formula during the first 6 months of life may reduce the risk of food allergy and atopic dermatitis up to the age of 5 years.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sekkidou Mikaela, Karglani Eva, Pancheva Rouzha, Kantaras Paris, Popova Simoneta, Zhelyazkova Desislava, Yiallouros Panayiotis K, Philippou Elena, Daniil Vasiliki, Boutsikou Theodora, Iliodromiti Zoi, Iacovidou Nicoletta, Papaevangelou Vassiliki, Manios Yannis, van Lee Linde, Nicolaou Nicolaos
Аннотация
BACKGROUND: Evidence on the effectiveness of partially hydrolyzed formulas (pHF) as a nutritional intervention to prevent Allergic Manifestations (AM) is limited. Provided that not all pHF are the same in terms of allergenicity and immunogenicity, their role in reducing the risk of the Atopic March progression should be individually and longitudinally examined.
OBJECTIVE: To investigate whether the risk-reduction effect of a specific pHF compared to a standard formula (SF) on Atopic Dermatitis (AD) within the first 6 months of life observed in the Allergy Reduction Trial (A.R.T.) persists at the age of 5 years and, if it applies to other AM.
METHODS: Parents/legal guardians of participants within the multicenter double-blinded randomized controlled clinical Allergy Reduction Trial (A.R.T.) who constituted the Intention-to-Treat population set (N = 551) were invited at the age of 5 years for an observational follow-up, to answer an enriched validated questionnaire regarding doctor diagnosis of AM between 1 and 5 years of age, including AD, Food Allergy (FA), Asthma, and Allergic Rhinitis (AR). The prevalence and cumulative incidence of outcomes were calculated and Relative Risks, 95% Confidence Interval (RR, 95% CI) were estimated by Poisson Generalized Estimating Equations adjusted for study center, sex, family history of AD, family history of AR, family history of Asthma, and mode of delivery.
RESULTS: Four hundred and fifty-five subjects (83%) completed the 5-year follow-up (pHF: 131/160, SF: 145/171 and EBF: 179/220). The RR from birth to 5 years was significantly lower in the pHF group, for the development of any AM [32.7% vs. 51.7%, RR 0.73 (0.57-0.94), p = .02], AD [22.1% vs. 38.5%, RR 0.58 (0.41-0.83), p = .003] and, FA [10.5% vs. 20.4%, RR 0.53 (0.29-0.95), p = .03] compared to the SF group. Infant feeding with the pHF resulted in 87% risk-reduction of FA [1.5% vs. 12.4%, RR 0.13 (0.03-0.58), p = .007] between the ages of 1-5 years.
CONCLUSION: In non-exclusively breastfed infants at high-risk for allergy, mixed-feeding with a specific whey-based pHF during the first 6 months of life may reduce the risk of atopic dermatitis and food allergy from birth up to the age of 5 years. However, further A.R.T. follow-ups and other longitudinal studies with larger sample size are needed to provide additional evidence for the long-term effectiveness of pHF in allergy prevention.
OBJECTIVE: To investigate whether the risk-reduction effect of a specific pHF compared to a standard formula (SF) on Atopic Dermatitis (AD) within the first 6 months of life observed in the Allergy Reduction Trial (A.R.T.) persists at the age of 5 years and, if it applies to other AM.
METHODS: Parents/legal guardians of participants within the multicenter double-blinded randomized controlled clinical Allergy Reduction Trial (A.R.T.) who constituted the Intention-to-Treat population set (N = 551) were invited at the age of 5 years for an observational follow-up, to answer an enriched validated questionnaire regarding doctor diagnosis of AM between 1 and 5 years of age, including AD, Food Allergy (FA), Asthma, and Allergic Rhinitis (AR). The prevalence and cumulative incidence of outcomes were calculated and Relative Risks, 95% Confidence Interval (RR, 95% CI) were estimated by Poisson Generalized Estimating Equations adjusted for study center, sex, family history of AD, family history of AR, family history of Asthma, and mode of delivery.
RESULTS: Four hundred and fifty-five subjects (83%) completed the 5-year follow-up (pHF: 131/160, SF: 145/171 and EBF: 179/220). The RR from birth to 5 years was significantly lower in the pHF group, for the development of any AM [32.7% vs. 51.7%, RR 0.73 (0.57-0.94), p = .02], AD [22.1% vs. 38.5%, RR 0.58 (0.41-0.83), p = .003] and, FA [10.5% vs. 20.4%, RR 0.53 (0.29-0.95), p = .03] compared to the SF group. Infant feeding with the pHF resulted in 87% risk-reduction of FA [1.5% vs. 12.4%, RR 0.13 (0.03-0.58), p = .007] between the ages of 1-5 years.
CONCLUSION: In non-exclusively breastfed infants at high-risk for allergy, mixed-feeding with a specific whey-based pHF during the first 6 months of life may reduce the risk of atopic dermatitis and food allergy from birth up to the age of 5 years. However, further A.R.T. follow-ups and other longitudinal studies with larger sample size are needed to provide additional evidence for the long-term effectiveness of pHF in allergy prevention.